

Rethinking Global Pharmaceutical Policy

William Fisher and Talha Syed

Contents

(version 3, January 4, 2025)

Preface

Part I

Chapter 1: The Global Health Crisis

- A. Vocabulary
- B. Threats
- C. Inequality

Chapter 2: The (Potential) Power of Drugs

- A. Achievements and Opportunities
- B. Misalignment
- C. Inaccessibility
- D. SFMPs
- E. Hesitancy

Chapter 3: Laws

- A. The U.S. Model
 - 1. Incentives
 - 2. Quality
 - 3. Access
 - 4. Gaps and Conflicts
- B. Other Countries
 - 1. High-Income
 - 2. Upper-Middle-Income
 - 3. Low and Lower-Middle-Income

Chapter 4: Responsibilities

- A. A Right to Health
- B. Responsibilities of Governments
- C. Responsibilities of Nongovernmental Organizations
 - 1. Philanthropies
 - 2. Companies

Part II

Chapter 5: Modifying Markets

- A. Expediting Approvals
- B. Surveillance
- C. Nudges

Chapter 6: Differential Pricing

- A. Background
- B. Differential Pricing of Drugs
- C. Reforms

Chapter 7: Voluntary Licensing

- A. History
 - 1. AIDS
 - 2. Hepatitis
 - 3. COVID
 - 4. NCDs
- B. Guidelines
 - 1. Multilateral Deals
 - 2. Selectivity
 - 3. Quality Control
 - 4. Local Production
 - 5. Technology Transfer
 - 6. Maximizing Impact
 - 7. Regulatory Approval
 - 8. Intellectual Property
 - 9. Transparency

Chapter 8: Adjusting Intellectual Property Systems

- A. Low-Income Countries
- B. High-Income Countries
- C. Middle-Income Countries

Chapter 9: Carrots

- A. Grants
- B. Prizes

Chapter 10: Sticks

- A. Justifications for Regulations
- B. Research Mandates
- C. Foreign Filing Licenses
- D. Price Regulation
- E. Benefit Sharing
- F. The Social-Responsibility Index

Conclusion

Appendices

1. Tuberculosis
2. Malaria
3. AIDS
4. Dengue
5. Ebola
6. COVID-19
7. Diabetes
8. Lung Cancer
9. Colorectal Cancer
10. Parkinson's Disease
11. Alzheimer's Disease and other forms of Dementia
12. Depression